Dongwha Pharm
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Dongwha Pharm makes prescription and over-the-counter medicines, medical devices, and distributes pharmaceutical products to hospitals, pharmacies, and other healthcare buyers across South Korea and overseas.
Listed on KOSPI, South Korea's main stock exchange, it operates through several business lines: a core pharmaceuticals division, a medical-device manufacturing subsidiary, a pharmaceutical distribution chain, and a small financial services unit. Pharmaceuticals account for the largest share of its consolidated revenue, with medical-device manufacturing and drug distribution making up most of the remainder.
Summary is AI-generated and may contain errors · figures from DART filings
Its medical-device subsidiary, Medissey, applies interdisciplinary engineering, combining clinical medicine with electrical, mechanical, materials, and optical technologies, to design and manufacture its products.
Dongwha Pharm in five facts
What does Dongwha Pharm do?
Dongwha Pharm makes prescription and over-the-counter medicines, medical devices, and distributes pharmaceutical products to hospitals, pharmacies, and other healthcare buyers across South Korea and overseas.
Where is Dongwha Pharm listed and in which sector?
Dongwha Pharm (Korean name: 동화약품) trades under KRX code 000020 on KOSPI, the main board of the Korea Exchange. It is classified in the Health Care sector, Pharmaceuticals.
How large is Dongwha Pharm?
Its market capitalisation was US$113.8M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Dongwha Pharm's latest annual revenue and operating profit?
For fiscal year 2025, Dongwha Pharm reported revenue of US$374.7M, operating profit of US$193.8K and net income of US$2.9M, per its annual report on DART (data retrieved from DART on 2026-09-05). Revenue was up 6.8% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-05
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- [Amended] Half-year report (2026.06)Oct 2
- [Amended] Cash/in-kind dividend decision
Dongwha Pharm updated its declared cash dividend of US$0.05 per share.
Dividend · Feb 24 · 2 versions - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Dongwha Pharm reported consolidated results for FY2025: revenue of US$344M (+6.78% year on year), operating profit of US$178K (−98.09% year on year) and net income of US$2.66M (+79.04% year on year).
Earnings · Feb 24